LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

Search

Erasca Inc

Closed

1.37 0.74

Overview

Share price change

24h

Current

Min

1.36

Max

1.4

Key metrics

By Trading Economics

Income

-1M

-32M

EPS

-0.11

Employees

103

EBITDA

1.5M

-35M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+259.71% upside

Dividends

By Dow Jones

Next Earnings

13 May 2025

Market Stats

By TradingEconomics

Market Cap

35M

448M

Previous open

0.63

Previous close

1.37

Technical Score

By Trading Central

Confidence

Bearish Evidence

Erasca Inc Chart

Past performance is not a reliable indicator of future results.

Related News

9 May 2025, 17:03 UTC

Earnings
Major Market Movers

Anika Therapeutics Shares Fall After Slump in 1Q Pain-Treatment Sales in U.S.

10 May 2025, 21:54 UTC

Top News

GOP Tax Bill Seeks to Put Cash in Taxpayers' Pockets in Early 2026 -- Update

10 May 2025, 17:12 UTC

Top News

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia to Cease Fire -- WSJ

10 May 2025, 12:00 UTC

Top News

Why a Sorority Is Taking on Trump's Budget Cuts -- WSJ

10 May 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

10 May 2025, 03:52 UTC

Top News

China Struggles With Persistent Disinflationary Pressures as Tariffs Bite -- WSJ

9 May 2025, 23:51 UTC

Acquisitions, Mergers, Takeovers

Oil at $50? The High Cost of Cheap Crude. -- Barrons.com

9 May 2025, 22:06 UTC

Market Talk

Arm Holdings Remains a Strong Growth Story -- Market Talk

9 May 2025, 21:37 UTC

Top News

U.S. Sets August Deadline for Debt Ceiling -- WSJ

9 May 2025, 21:10 UTC

Top News

The Score: Disney, Berkshire Hathaway, Ford and More Stocks That Defined the Week -- WSJ

9 May 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9 May 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

9 May 2025, 20:42 UTC

Top News

Stocks Get a Break From Trade Chaos -- WSJ

9 May 2025, 20:21 UTC

Top News

Trump Floats Lowering China Tariffs to 80%, Says Many Trade Deals to Come -- WSJ

9 May 2025, 19:23 UTC

Market Talk

Oil Snaps Losing Streak on Optimism Over Trade Talks -- Market Talk

9 May 2025, 19:01 UTC

Market Talk

U.S. Natural Gas Posts Second Weekly Gain -- Market Talk

9 May 2025, 18:56 UTC

Earnings

Dr Reddy's Laboratories 4Q EPS INR19.11 >RDY

9 May 2025, 18:56 UTC

Earnings

Dr Reddy's Laboratories 4Q Rev INR85.06B >RDY

9 May 2025, 18:52 UTC

Market Talk

Gold Resumes Upward Momentum -- Market Talk

9 May 2025, 18:12 UTC

Market Talk

Lower Diesel Prices Provide Some Relief for Truckers -- Market Talk

9 May 2025, 18:02 UTC

Top News

Trump Floats 80% China Tariff, Says Many Trade Deals 'In the Hopper' -- WSJ

9 May 2025, 17:30 UTC

Market Talk

U.S. Oil Rig Count Falls by 5 to 474 -- Market Talk

9 May 2025, 17:21 UTC

Earnings

Trade Desk Stock Is Surging on Earnings. There Are 'Significant Opportunities.' -- Barrons.com

9 May 2025, 17:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 May 2025, 17:14 UTC

Market Talk

Canada's Softening Labor Data May Not Clinch Another Rate Cut -- Market Talk

9 May 2025, 17:12 UTC

Market Talk

Mexican Industrial Production Seen Mixed in March -- Market Talk

9 May 2025, 16:51 UTC

Earnings
Acquisitions, Mergers, Takeovers

Affirm's Weak Guidance Hits the Stock. Why This Analyst Upgraded the Shares. -- Barrons.com

9 May 2025, 16:50 UTC

Earnings

Turkcell Iletisim Hizmetleri 1Q Net TRY3.08B >TKC

9 May 2025, 16:49 UTC

Earnings

Turkcell Iletisim Hizmetleri 1Q Rev TRY47.96B >TKC

9 May 2025, 16:49 UTC

Market Talk

Weak Canadian Employment Trend Continues, Seen Leaving Door Open to Rate Cut -- Market Talk

Peer Comparison

Price change

Erasca Inc Forecast

Price Target

By TipRanks

259.71% upside

12 Months Forecast

Average 5 USD  259.71%

High 6 USD

Low 4 USD

Based on 5 Wall Street analysts offering 12 month price targets forErasca Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

1.39 / 1.44Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Very Strong Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.